Dr Paul de Souza from New South Wales, Australia, discusses aspects of the androgen signalling pathway in castration resistant prostate cancer (CRPC), emphasising that androgen pathway signalling remains a major target for prostate cancer therapy due to its now-established role as a key driver in CRPC. He explains the androgen receptor structure and the complex signalling mechanism; also the changes to this in various stages of CRPC, eg, androgen receptor hypersensitivity and promiscuity, and bypass pathways. Dr de Souza explores how this target can be attacked with therapeutic androgen receptor blockers, such as abiraterone and enzalutamide, as well as newer agents, such as galeterone and HSP90.

This video is sponsored by an educational grant from Janssen Asia Pacific, a pharmaceutical company of Johnson & Johnson